EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieÄquivalenzstudieMultizentrische Studie

Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment

Carol Wysham, Harpreet S Bajaj, Stefano Del Prato iD, Denise Reis Franco, Arihiro Kiyosue, Dominik Dahl, Chunmei Zhou, Molly C Carr, Michael Case, Livia Firmino Gonçalves, QWINT-2 Investigators

New England Journal of Medicine · 12.12.2024 · 391 (23) · 2201-2211

DOI: 10.1056/nejmoa2403953 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 12.12.2024. Verfasst von Carol Wysham und 10 weiteren Autor:innen. Beteiligte Einrichtung: From the MultiCare Rockwood Center for Diabetes and Endocrinology, Spokane, WA (C.W.); LMC Diabetes and Endocrinology, Brampton, ON, Canada (H.S.B.);…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemia, Hypoglycemic Agents. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Insulin efsitora alfa (efsitora) is a new basal insulin designed for once-weekly administration. Data on safety and efficacy have been limited to small, phase 1 or phase 2 trials. METHODS: We conducted a 52-week, phase 3, parallel-design, open-label, treat-to-target trial involving adults with type 2 diabetes who had not previously received insulin. Participants were randomly assigned in a 1:1 ratio to receive efsitora or degludec. The primary end point was the change in the glycated hemoglobin level from baseline to week 52; we hypothesized that efsitora would be noninferior to degludec (noninferiority margin, 0.4 percentage points). Secondary and safety end points included the change in the glycated hemoglobin level in subgroups of participants using and not using glucagon-like peptide-1 (GLP-1) receptor agonists, the percentage of time that the glucose level was in the target range of 70 to 180 mg per deciliter in weeks 48 through 52, and hypoglycemic episodes. RESULTS: A total of 928 participants underwent randomization (466 to the efsitora group and 462 to the degludec group). The mean glycated hemoglobin level decreased from 8.21% at baseline to 6.97% at week 52 with efsitora (least-squares mean change, -1.26 percentage points) and from 8.24% to 7.05% with degludec (least-squares mean change, -1.17 percentage points) (estimated treatment difference, -0.09 percentage points; 95% confidence interval [CI], -0.22 to 0.04), findings that showed noninferiority. Efsitora was noninferior to degludec with respect to the change in the glycated hemoglobin level in participants using and not using GLP-1 receptor agonists. The percentage of time that the glucose level was within the target range was 64.3% with efsitora and 61.2% with degludec (estimated treatment difference, 3.1 percentage points; 95% CI, 0.1 to 6.1). The rate of combined clinically significant or severe hypoglycemia was 0.58 events per participant-year of exposure with efsitora and 0.45 events per participant-year of exposure with degludec (estimated rate ratio, 1.30; 95% CI, 0.94 to 1.78). No severe hypoglycemia was reported with efsitora; six episodes were reported with degludec. The incidence of adverse events was similar in the two groups. CONCLUSIONS: In adults with type 2 diabetes who had not previously received insulin, once-weekly efsitora was noninferior to once-daily degludec in reducing glycated hemoglobin levels. (Funded by Eli Lilly; QWINT-2 ClinicalTrials.gov number, NCT05362058.).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glycated HemoglobinHypoglycemiaHypoglycemic AgentsInsulin, Long-ActingAgedFemaleHumansMaleMiddle AgedBlood GlucoseGlucagon-Like Peptide-1 Receptor AgonistsDrug Administration Schedule

Substanzen

Blood GlucoseGlycated HemoglobinHypoglycemic Agentsinsulin degludecInsulin, Long-ActingGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • From the MultiCare Rockwood Center for Diabetes and Endocrinology, Spokane, WA (C.W.); LMC Diabetes and Endocrinology, Brampton, ON, Canada (H.S.B.); the Interdisciplinary Research Center for Health Science, Sant'Anna S…

ORCID-Profile: Stefano Del Prato

Förderung

  • Eli Lilly and Company

Zitieren

APA

Wysham, C., Bajaj, H. S., Del Prato, S., Franco, D. R., Kiyosue, A., Dahl, D., Zhou, C., Carr, M. C., Case, M., Firmino Gonçalves, L., & QWINT-2 Investigators (2024). Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment. New England Journal of Medicine, 391(23), 2201-2211. https://doi.org/10.1056/nejmoa2403953

Vancouver

Wysham C, Bajaj HS, Del Prato S, Franco DR, Kiyosue A, Dahl D, et al. Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment. New England Journal of Medicine. 2024;391(23):2201-2211. doi:10.1056/nejmoa2403953

BibTeX
@article{Wysham2024,
  author = {Wysham, Carol and Bajaj, Harpreet S and Del Prato, Stefano and Franco, Denise Reis and Kiyosue, Arihiro and Dahl, Dominik and Zhou, Chunmei and Carr, Molly C and Case, Michael and Firmino Gonçalves, Livia and QWINT-2 Investigators, QWINT-2 Investigators},
  title = {Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {23},
  pages = {2201--2211},
  doi = {10.1056/nejmoa2403953}
}
Kostenlos starten →